4 results  1 of 1 

1 Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome?
Eryn Sara Rubenfeld, Michael Haim Dahan
Obstet Gynecol Sci.2021;64(4):345-352.   Published online 2021 June 9     DOI: http://dx.doi.org/10.5468/ogs.21067
      
2 Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
Youngki Lee, Cheol Ryong Ku, Eui-Hyun Kim, Jae Won Hong, Eun Jig Lee, Sun Ho Kim
Endocrinol Metab.2014;29(3):280-292.   Published online 2014 September 25     DOI: http://dx.doi.org/10.3803/EnM.2014.29.3.280
      
3 Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
Kyung Rae Cho, Kyung-Il Jo, Hyung Jin Shin
Brain Tumor Res Treat.2013;1(2):71-77.   Published online 2013 October 31     DOI: http://dx.doi.org/10.14791/btrt.2013.1.2.71
      
4 Efficacy and Safety of Cabergoline as First Line Treatment for Invasive Giant Prolactinoma
Eun-Hee Cho, Sang Ah Lee, Ji Youn Chung, Eun Hee Koh, Young Hyun Cho, Jeong Hoon Kim, Chang Jin Kim, Min-Seon Kim
J Korean Med Sci.2009;24(5):874-878.   Published online 2009 September 24     DOI: http://dx.doi.org/10.3346/jkms.2009.24.5.874
      

 1 of 1